哌拉西林/他唑巴坦与危重患儿抗生素相关急性肾损伤
本研究为回顾性队列研究,纳入5686例危重患儿,比较哌拉西林/他唑巴坦(TZP)或头孢吡肟(联合或不联合万古霉素)暴露后急性肾损伤(AKI)的发生率。结果显示TZP暴露与AKI风险增加相关(校正OR 1.56,95%CI 1.23-1.99),头孢吡肟未显示显著关联,万古霉素联合TZP相比联合头孢吡肟的OR为1.38(95%CI 0.85-2.24),差异无统计学意义。
要点
- 危重患儿使用TZP与AKI风险增加独立相关(校正OR 1.56)。
- 头孢吡肟未显示与AKI风险增加相关(校正OR 1.13,95%CI 0.79-1.64)。
- 万古霉素联合TZP与联合头孢吡肟的AKI风险差异无统计学意义。
核心结论
- 观察性数据显示危重患儿使用TZP与AKI风险增加相关。
- 万古霉素联合TZP相比联合头孢吡肟的AKI关联较弱且无统计学意义,提示TZP与AKI关联存在不确定性。
- 头孢吡肟是与AKI无显著关联的替代选择。
研究设计与样本
- 回顾性队列研究,纳入儿科重症监护病房患者5686例,评估入院48小时内暴露于万古霉素、TZP和头孢吡肟(单用或联用)后AKI风险。
主要发现
- 494例(8.7%)发生2期或3期AKI。
- TZP暴露后发生AKI的校正OR为1.56(95%CI 1.23-1.99)。
- 头孢吡肟暴露后发生AKI的校正OR为1.13(95%CI 0.79-1.64)。
- 万古霉素暴露后发生AKI的校正OR为0.86(95%CI 0.69-1.07)。
- 万古霉素联合TZP相比万古霉素联合头孢吡肟发生AKI的校正OR为1.38(95%CI 0.85-2.24)。
临床怎么用
- 危重患儿使用TZP时需警惕AKI风险,可考虑头孢吡肟作为替代选择。
- 联合使用万古霉素时,TZP与头孢吡肟的AKI风险差异不显著,但TZP单用风险较高。
局限性
- 本研究为观察性设计,可能存在残余混杂。
- 万古霉素联合TZP与联合头孢吡肟的比较无统计学意义,关联性质不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There continues to be uncertainty about whether piperacillin/tazobactam (TZP) increases the risk of AKI in critically ill pediatric patients. We sought to compare rates of AKI among critically ill children treated with TZP or cefepime, an alternative frequently used in intensive care units, with and without vancomycin. METHODS: We conducted a retrospective cohort study assessing the risk of AKI in pediatric intensive care unit patients after exposure to vancomycin, TZP, and cefepime, alone or in combination, within 48 hours of admission. The primary outcome was development of stage 2 or 3 AKI or an increase in AKI stage from 2 to 3 within the 6 days after the 48-hour exposure window. Secondary outcomes included lengths of stay, need for RRT, and mortality. RESULTS: Of 5686 patients included, 494 (8.7%) developed stage 2 or 3 AKI. The adjusted odds of developing AKI after medication exposure were 1.56 for TZP (95% confidence interval [95% CI], 1.23 to 1.99), 1.13 for cefepime (95% CI, 0.79 to 1.64), and 0.86 for vancomycin (95% CI, 0.69 to 1.07). The adjusted odds of developing AKI for vancomycin plus TZP versus vancomycin plus cefepime was 1.38 (95% CI, 0.85 to 2.24). CONCLUSIONS: Observational data in critically ill children show that TZP use is associated with increased odds of AKI. A weaker, nonsignificant association between vancomycin plus TZP and AKI compared with vancomycin plus cefepime, creates some uncertainty about the nature of the association between TZP and AKI. However, cefepime is an alternative not associated with AKI.
引用
- Joyce EL, Kane-Gill SL, Priyanka P, et al. Piperacillin/Tazobactam and Antibiotic-Associated Acute Kidney Injury in Critically Ill Children. J Am Soc Nephrol. 2019. PMID: 31501354. doi:10.1681/ASN.2018121223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。